This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
Download2014
Shroff, R., Katz, M. H., Overman, M. J., Khalil, M., Lieffers, J., Varadhachary, G. R., Fogelman, D., Javle, M. , Holmes, H., Prado, C. M.
BackgroundIGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.MethodsWe evaluated muscle mass at L3 in patients enrolled in a randomized phase...